Sökning: WFRF:(Tyrstrup Mia) >
Clinical course of ...
-
Tell, DavidLinköpings universitet,Linköping University,Institutionen för hälsa, medicin och vård,Medicinska fakulteten,Futurum, Reg Jonkoping Cty, Sweden
(författare)
Clinical course of pharyngotonsillitis with group A streptococcus treated with different penicillin V strategies, divided in groups of Centor Score 3 and 4: a prospective study in primary care
- Artikel/kapitelEngelska2022
Förlag, utgivningsår, omfång ...
-
2022-11-11
-
Springer Science and Business Media LLC,2022
Nummerbeteckningar
-
LIBRIS-ID:oai:gup.ub.gu.se/320536
-
https://gup.ub.gu.se/publication/320536URI
-
https://doi.org/10.1186/s12879-022-07830-4DOI
-
https://lup.lub.lu.se/record/cb74396a-85f1-4849-b150-dab3224726f5URI
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-190203URI
Kompletterande språkuppgifter
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Funding Agencies|Public Health Agency of Sweden; Region Jonkoping County
-
Background Sore throat is a common reason for prescribing antibiotics in primary care, and 10 days of treatment is recommended for patients with pharyngotonsillitis with group A streptococcus (GAS). Our group recently showed that penicillin V (PcV) four times daily for 5 days was non-inferior in clinical outcome to PcV three times daily for 10 days. This study compares duration, intensity of symptoms, and side effects in patients with a Centor Score (CS) of 3 or 4 respectively, after treatment with PcV for 5 or 10 days and evaluates whether all patients with pharyngotonsillitis with a CS of 3 or 4 should be treated for 5 days or if severity of symptoms or CS suggest a longer treatment period. Method Data on symptoms and recovery from patient diaries from 433 patients included in a RCT comparing PcV 800 mg x 4 for 5 days or PcV 1 g x 3 for 10 days was used. Patients six years and older with CS-3 or CS-4 and positive rapid antigen detection test for GAS-infection were grouped based on CS and randomized treatment. Comparisons for categorical variables were made with Pearson's chi-squared test or Fisher's exact test. Continuous variables were compared with the Mann-Whitney U test. Results Patients with CS-3 as well as patients with CS-4 who received PcV 800 mg x 4 for 5 days self-reported that they recovered earlier compared to patients with CS-3 or CS-4 who received treatment with PcV 1 g x 3 for 10 days. In addition, the throat pain as single symptom was relieved 1 day earlier in patients with CS-4 and 5 days of treatment compared to patients with CS-4 and 10 days of treatment. No differences in side effects between the groups were found. Conclusion Intense treatment with PcV four times a day for 5 days seems clinically beneficial and strengthens the suggestion that the 4-dose regimen with 800 mg PcV for 5 days may be the future treatment strategy for GAS positive pharyngotonsillitis irrespectively of CS-3 or CS-4. Trail registration ClinicalTrials.gov ID: NCT02712307 (3 April 2016).
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Tyrstrup, MiaLund University,Lunds universitet,Allmänmedicin och samhällsmedicin,Forskargrupper vid Lunds universitet,Family Medicine and Community Medicine,Lund University Research Groups,Lund Univ, Sweden(Swepub:lu)med-mty
(författare)
-
Edlund, C.Public Health Agency of Sweden
(författare)
-
Rystedt, KarinUniversity of Gothenburg,Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för samhällsmedicin och folkhälsa,CARe - Centrum för antibiotikaresistensforskning,Institute of Medicine, School of Public Health and Community Medicine,Centre for antibiotic resistance research, CARe,Sahlgrenska Academy,Univ Gothenburg, Sweden; Primary Hlth Care, Sweden; Univ Gothenburg, Sweden
(författare)
-
Stahlgren, G. S.Public Health Agency of Sweden
(författare)
-
Sundvall, Pär-DanielUniversity of Gothenburg,Gothenburg University,Göteborgs universitet,CARe - Centrum för antibiotikaresistensforskning,Institutionen för medicin, avdelningen för samhällsmedicin och folkhälsa,Centre for antibiotic resistance research, CARe,Institute of Medicine, School of Public Health and Community Medicine,Sahlgrenska Academy,Univ Gothenburg, Sweden; Primary Hlth Care, Sweden; Univ Gothenburg, Sweden(Swepub:gu)xsupar
(författare)
-
Hedin, KatarinaLinköpings universitet,Linköping University,Lund University,Lunds universitet,Allmänmedicin och samhällsmedicin,Forskargrupper vid Lunds universitet,Family Medicine and Community Medicine,Lund University Research Groups,Region Jönköping County,Avdelningen för prevention, rehabilitering och nära vård,Medicinska fakulteten,Futurum, Reg Jonkoping Cty, Sweden; Lund Univ, Sweden(Swepub:liu)kathe53
(författare)
-
Linköping UniversityInstitutionen för hälsa, medicin och vård
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:BMC Infectious Diseases: Springer Science and Business Media LLC22:11471-2334
Internetlänk
Hitta via bibliotek
Till lärosätets databas